Gossamer Bio said its 1-for-80 reverse stock split became effective at 11:59 p.m. Eastern on Sept. 10, 2026, with split-adjusted trading expected to begin Sept. 11 under the existing ticker “GOSS.”
Every 80 shares outstanding immediately before the split were combined into 1 share. The company also cut its authorized common stock to 50 million shares from 4 billion, and total authorized capital stock to 120 million from 4.07 billion.
The split also triggered proportional adjustments to the company’s capital structure. Conversion rates on its 5.00% convertible senior notes due 2027 and 7.50% convertible senior secured first lien notes due 2030 were adjusted, along with the share counts and exercise prices tied to outstanding warrants, prefunded warrants and equity awards. Shares reserved for future issuance under equity incentive plans were reduced proportionately.
Gossamer said the split was intended to help it regain compliance with Nasdaq’s minimum bid price requirement. To do so, the stock must close at at least $1.00 for 10 consecutive business days before the Oct. 5, 2026 compliance date. The company’s shares last traded before the split under the same ticker, with a new CUSIP number now in place. The market has reacted to these announcements by moving the company's shares -6.43% to a price of $10.66. Check out the company's full 8-K submission here.
